Hm. Wexler et al., IN-VITRO ACTIVITY OF CLINAFLOXACIN (CI-960) AND PD-131628-2 AGAINST ANAEROBIC-BACTERIA, Journal of antimicrobial chemotherapy, 34(4), 1994, pp. 579-584
The antimicrobial activities of two new quinolones, CI-960 and PD 1316
28-2 were determined against 339 strains of anaerobic bacteria and com
pared to cefoxitin, imipenem and metronidazole. The NCCLS-approved Wad
sworth agar dilution technique with Brucella-lysed blood agar was used
throughout the study. Breakpoints of the new quinolones are 2 mg/L, a
nd breakpoints for cefoxitin, imipenem and metronidazole are 32, 8 and
16 mg/L, respectively. CI-960 displayed excellent activity, inhibitin
g all strains tested at 1 mg/L. PD 131628-2 inhibited 94% of Bacteroid
es fragilis, 75% of other B. fragilis group isolates, 87% of Prevotell
a spp, 79% of the Fusobacterium mortiferum-varium group, 74% of non-sp
oring gram-positive bacilli, and 89-100% of Clostridium spp other than
Clostridium difficile at 2 mg/L. None of the eight strains of C. diff
icile was inhibited at 2 mg/L although they were inhibited at 4 mg/L.
PD 131628-2 inhibited all strains of other Bacteroides spp, Porphyromo
nas spp, and Fusobacterium nucleatum at less than or equal to 1 mg/L.